FOXD2‐AS1 competes with the 3'UTR of TMEM9 for binding with miR‐150‐5p, which promotes the expression of TMEM9, inhibits the Nrf2‐ARE signalling pathway, and reverses sorafenib resistance in HCC cells. This evidence concerns the gene TMEM9 and hepatocellular carcinoma.